Last reviewed · How we verify
Intermittent Meropenem
At a glance
| Generic name | Intermittent Meropenem |
|---|---|
| Also known as | Intermittent Infusion of Meropenem, Kener, Merrem, AstraZeneca |
| Sponsor | Coordinación de Investigación en Salud, Mexico |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Bolus Versus Continuous Infusion of Meropenem (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia (PHASE4)
- A Pharmacokinetics Study of Meropenem and Piperacillin in Patients With Sepsis
- Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia (PHASE4)
- Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis (NA)
- Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intermittent Meropenem CI brief — competitive landscape report
- Intermittent Meropenem updates RSS · CI watch RSS
- Coordinación de Investigación en Salud, Mexico portfolio CI